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ABSTRACT  
Objective: To estimate the degree of axonal loss in patients diagnosed with multifocal motor 
neuropathy (MMN) using a novel assessment of motor unit numbers and size. Methods: 
Automated motor unit number estimation using a compound muscle action potential (CMAP) 
scan was undertaken in median nerves with conduction block. Results were compared with 
30 age-matched healthy controls. Results: Compared with healthy controls, MMN patients 
had fewer motor units (MMN: 33 ± 11 vs HC: 93 ± 36 [mean ± SD]; p<0.0001) and larger 
‘size of the largest unit’ (MMN: 1.2 ± 0.5mV vs HC: 0.4 ± 0.1mV; p<0.0001), despite having 
normal distal CMAP amplitudes (MMN: 7.6 ± 1.8mV vs HC: 8.7 ± 2.5mV; p=0.24). 
Conclusions: MMN is associated with marked axonal loss which may be masked by striking 
re-innervation resulting in preservation of distal CMAP amplitudes. Significance: Assessment 
of motor unit properties should be incorporated into assessment of disease progression in 
MMN, given that nerve conduction studies are insensitive to motor unit remodelling. 
 
Keywords: Neurophysiology; neuromuscular disease; autoimmune diseases; multifocal 
motor neuropathy; axonal degeneration. 
 
Highlights 
 Axonal degeneration is an integral part of the disease process in MMN. 
 Axonal loss in MMN may be masked by prominent re-innervation. 
 Nerve conduction studies are not sensitive to motor unit remodelling in MMN. 
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1. INTRODUCTION 
Progressive axonal degeneration is a prominent feature of multifocal motor neuropathy 
(MMN), differentiating it from the other immune-mediated neuropathies (Vlam et al., 2011). 
The aim of immunomodulatory treatment with intravenous immunoglobulin (IVIg) has been 
to reduce the rate of axonal loss as this is the most important determinant of permanent 
weakness and disability (Van Asseldonk et al., 2006; Vucic et al., 2004). It has been 
suggested that the effectiveness of IVIg may decline over time, correlating with the 
development of axonal degeneration (Terenghi et al., 2004). 
 
Unfortunately, mechanisms of conduction block and axonal degeneration in MMN remain 
poorly understood and there remains debate as to whether MMN is primarily a demyelinating 
or axonal disorder (Kiernan et al., 2002). Anti-GM1 IgM is present in approximately 50% of 
patients with MMN with GM1 enriched in the nodal and paranodal regions (Vlam et al., 
2011; Willison and Yuki, 2002). It has recently been suggested that disease processes 
targeting these regions represent a distinct group of neuropathies characterised by a 
continuum from conduction block to axonal degeneration, a concept which may be pivotal in 
understanding the pathophysiology of conditions such as MMN (Uncini and Kuwabara, 
2015).  
 
Axonal loss is typically only identified late in the disease process and only once the 
compound muscle action potential (CMAP) amplitude has reduced on nerve conduction 
studies (NCS). The present study was prompted by the frustration at the lack of an objective 
method to monitor treatment response and disease progression in MMN patients. As such, a 
novel technique was utilised to quantify the degree of axonal loss and compensatory 
reinnervation in MMN as a potential tool for disease monitoring. 
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2. METHODS 
2.1. Patient cohort and selection criteria 
Consecutive patients fulfilling European Federation of Neurological Societies/Peripheral 
Nerve Society criteria for MMN (definite or probable) were prospectively recruited between 
April 2015 and December 2016. Cases of ‘possible’ MMN were excluded (Joint Task Force 
of the EFNS and the PNS, 2010).  Results were compared with 30 healthy control subjects 
who were screened based on their medical history. All participants gave written informed 
consent to participate in the study. The study was approved by the Sydney Local Health 
District Ethics Review Committee (Royal Prince Alfred Hospital). 
 
2.2. Assessment Tools 
Muscle strength was assessed using Medical Research Council (MRC) grading by a single 
investigator (N.G.) in 15 muscle groups bilaterally (shoulder abduction, elbow flexion, elbow 
extension, wrist flexion, wrist extension, finger extension, finger flexion, first dorsal 
interosseus, abductor digiti minimi, thumb abduction, hip flexion, knee flexion, knee 
extension, ankle dorsiflexion and ankle plantarflexion). The MRC grades were summed to 
calculate an expanded MRC sum-score (maximum score 150). Serum from each patient was 
tested for anti-GM1 IgM antibodies as previously described (Yuki et al., 1997). 
 
2.3. Nerve conduction studies 
All patients underwent NCS at the time of recruitment by a single 
neurologist/neurophysiologist (N.G.) to ensure criteria for MMN were fulfilled and to 
identify median nerves with conduction block within the forearm segment. All patients had 
motor NCS of the median nerves bilaterally with stimulation at the wrist and elbow and 
recording over abductor pollicis brevis. In addition, patients underwent ulnar, common 
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peroneal and tibial motor studies and median, ulnar and radial sensory studies unilaterally. 
Conduction block was defined as negative peak CMAP area reduction of at least 30% on 
stimulation of wrist versus elbow with duration increase of 30% or less, or CMAP area 
reduction of 50% when CMAP duration increase was greater than 30% (Joint Task Force of 
the EFNS and the PNS, 2010).  
 
2.4. Assessment of motor unit properties using a novel CMAP scan 
CMAP scans (Bostock, 2016) were recorded using the TRONDNF protocol within 
QTRACW software (© Institute of Neurology, University College London, UK). All 
recordings were undertaken by stimulating the median nerve at the wrist with a 0.2 ms wide 
stimulus using an isolated constant current stimulator (DS5; Digitimer, Welwyn Garden City, 
UK). The active recording electrode was placed over the motor point of abductor pollicis 
brevis and reference electrode over the proximal phalanx. The stimulus strength was 
manually increased until the supramaximal CMAP was reached. Following this, stimuli were 
delivered twice per second with each stimulus intensity being 99.8% of the preceding 
stimulus until no response was recordable. 20 pre- and post-scan sweeps were recorded to 
assess variability of supramaximal (MScan Peak) and baseline responses respectively with 
each scan taking approximately 5 minutes in total. 
 
The MScanFit program contained within the QTRACW software was used to derive a motor 
unit number estimate (MUNE), and Size of the largest unit (in mV and as a percentage of the 
MScan Peak). The program uses a mathematical model to simulate the recorded scan. The 
modelled scan is then ‘fitted’ to the recorded scan by making sequential adjustments until the 
discrepancy between the two scans is minimised as previously described (Bostock, 2016).  
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Median nerves with forearm conduction block were selected for the current study as this is a 
frequent site of involvement in typical MMN and the forearm segment is not a typical site of 
entrapment neuropathy. Median nerves with distal motor latency prolongation on NCS 
(>4ms) were excluded due to the possibility of entrapment neuropathy at the wrist. In patients 
with bilateral median nerve forearm CB, only results from one side were used in the analysis.  
 
2.5. Statistics 
An independent samples t-test was used to compare age, MScan Peak and MUNE between 
MMN patients and healthy controls. Results of the Size of the largest unit were not normally 
distributed in MMN patients. Hence, the Mann-Whitney U test was used. Pearson correlation 
coefficient was used to investigate the relationship between MUNE, MScan Peak and age 
followed by linear regression analysis. Significance was defined by a p-value of <0.05. 
Results are presented as mean ± standard deviation. Statistical analysis and graph 
construction was performed using Graph Pad Prism 7 and IBM SPSS Statistics (Version 22). 
 
3. RESULTS 
A total of 12 patients fulfilling EFNS/PNS criteria for definite or probable MMN were 
recruited. All MMN patients were established and controlled on maintenance IVIg therapy. 
Ten patients were identified with median nerve motor conduction block in the forearm. Two 
patients had high thresholds limiting supramaximal stimulation and hence accurate motor unit 
number estimation could not be calculated. The remaining eight patients underwent median 
nerve CMAP scans on the ipsilateral side of conduction block. Clinical and laboratory 
features of the patients were typical of MMN (Table 1). Results were compared with 
recordings from 30 healthy controls [13:17 (M:F)] who were of similar age (MMN: 54.6 ± 
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13.6; HC: 55.1 ± 16.5; p = ns). 63% of MMN patients were positive for anti-GM1 IgM. The 
mean IVIg dose was 0.9 ± 0.4 grams/kg/4-weeks.  
 
3.1. Nerve Conduction Studies 
Median nerve conduction data for MMN patients (summarised in Table 2) confirmed that all 
patients had well preserved median nerve distal CMAP amplitudes > 5mV, with a mean distal 
CMAP of 8.05 ± 1.9 mV (range 6.3 – 11.2) and mean area reduction 54% ± 22 (range 30 – 
93%). The precise site of conduction block was unable to be accurately localised in the 
majority of patients due to the deep location of the median nerve within the forearm.  
 
3.2. Results of CMAP Scan 
Compared with healthy controls, there was no difference in the maximal response (MScan 
Peak) in the MMN group (MMN: 7.6 ± 1.8 mV vs HC: 8.7 ± 2.5 mV; p=0.24) (Figure 1A). 
However, MMN patients had a markedly reduced number of units having only a third of the 
number of units that were seen in HC subjects (MMN: 33 ± 11 vs HC: 93 ± 36; p<0.0001) 
(Figure 1B, Tables 2 and 3). In addition, MMN patients exhibited a strikingly larger size of 
the largest unit compared with healthy controls (MMN: 1.2 ± 0.5 mV vs HC: 0.4 ± 0.1 mV; 
p<0.0001) (Figure 1C, D) demonstrating that despite substantial axonal loss, significant 
reinnervation had occurred maintaining a normal distal CMAP. An example of the CMAP 
scan in an MMN subject and a healthy control are presented in Figure 2. 
 
3.3. Correlations between clinical features and neurophysiology 
There was a positive correlation between MUNE and MScan Peak in the HC group (R = 0.69; 
p < 0.0005) and a negative correlation between age and MUNE (R = - 0.65; p < 0.0005). 
These correlations were lost in the MMN group (Figure 3). No correlation was found 
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between MUNE or Size of largest unit and clinical features such as disease duration or 
expanded MRC sum-score in the MMN patients.  
 
4. DISCUSSION 
The present study highlights the marked reduction in the number of motor units innervating a 
muscle affected by conduction block in MMN despite preservation of the distal CMAP 
amplitude. The degree of axonal loss suggests that the axon may be a direct target in MMN.  
Furthermore, it demonstrates the striking collateral reinnervation by surviving motor units 
compensating for and potentially masking axon loss that has occurred.  
 
The immune basis for MMN is supported by the association with anti-GM1 IgM antibody and 
response to immunomodulatory therapy. GM1 is enriched in the nodal and paranodal regions 
(Willison and Yuki, 2002) and gangliosides play an important role in the maintenance and 
stabilisation of the paranode and ion channel clustering (Susuki et al., 2007). Conduction 
block may result from a variety of processes such as lengthening of the node, detachment of 
myelin from the paranode, sodium channel dysfunction and/or abnormalities in axolemma 
polarisation (Barnett et al., 2016; Uncini and Kuwabara, 2015) and in theory, pathology at 
either the node and/or the paranode could lead to conduction failure and axonal degeneration.  
Axonal degeneration has been shown to be strongly associated with conduction block 
supporting the notion that the same pathophysiology may account for both processes (Vucic 
et al., 2007; Van Asseldonk et al., 2006) and the continuum from conduction block to axonal 
degeneration with disease processes affecting the nodal/paranodal regions has recently 
become better recognised as a distinct entity (Uncini and Kuwabara, 2015).  
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Only a small number of conflicting reports have described the histopathology of motor fibres 
in MMN (Vlam et al., 2011). While one study found predominantly axonal pathology (Taylor 
et al., 2004), two others reported evidence of demyelination along with onion bulb formations 
(Corbo et al., 1997; Kaji et al., 1993). In two histopathology studies regenerative fibre 
clusters were reported in MMN (Corbo et al., 1997; Taylor et al., 2004), changes which were 
not seen in biopsies taken from patients with motor neuron disease (Corbo et al., 1997), 
highlighting that motor nerve regeneration is a prominent feature of MMN.  
 
Axonal degeneration is a key area of interest in MMN as it is the major determinant of 
permanent weakness and disability (Cats et al., 2010; Van Asseldonk et al., 2006). 
Traditionally, axon loss has been heralded by a reduction in the distal CMAP amplitude (Cats 
et al., 2010; Terenghi et al., 2004). The present study highlights that axonal loss may be 
prominent before a reduction in CMAP amplitude reinforcing the notion that nerve 
conduction studies may be suboptimal in monitoring disease progression and treatment 
response. In one study, needle electromyography (EMG) was shown to be more sensitive in 
detecting axonal loss than assessment of distal CMAP amplitude with EMG abnormalities 
demonstrated in patients with short disease duration. Furthermore, in the same study, 90% of 
patients had EMG signs of reinnervation (Van Asseldonk et al., 2006). The results of the 
present study are consistent with these findings. However, while EMG should show a 
reduction in motor units and increase in size of units, it is not a practical tool for long-term 
monitoring. 
 
IVIg remains the mainstay of therapy for MMN with studies demonstrating its efficacy in 
improving muscle strength and neurophysiological parameters, although in some series this 
has been followed by a slow decline in CMAP amplitudes and muscle scores (Terenghi et al., 
  
Garg, Page 11 
 
11 
 
2004; Van den Berg-Vos et al., 2002). It has been reported that the effect of IVIg often 
declines over time and progressive wasting and weakness may ensue despite increasing doses 
of IVIg (Cats et al., 2010; Terenghi et al., 2004). It has however, been demonstrated that early 
institution of higher doses of IVIg may prevent this decline by promoting reinnervation 
(Vucic et al., 2004). The general approach in clinical practice for patients established on 
IVIg, is to escalate treatment by increasing IVIg dosing or frequency only once a patient 
clinically deteriorates (Burrell et al., 2011).  However, once distal CMAP reductions occur 
and disability ensues, it is possible that the capacity for repair has largely been exhausted and 
hence escalating treatment during this stage of the disease may be inadequate.  
 
The CMAP Scan is a new technique for MUNE estimation which is practical and fast to 
perform, taking only approximately 5 minutes. MUNE values, particularly when small, are 
accurately estimated with a mean absolute error of less than 7% (Bostock, 2016). The CMAP 
Scan method has been shown to have good reproducibility in ALS with inter and intra-rater 
reproducibility exceeding that of other methods of motor unit number estimation, including 
multiple point stimulation MUNE (MPS) and motor unit number index (MUNIX) (Jacobsen, 
2017). 
 
MPS and MUNIX have been used to demonstrate axonal loss and reinnervation in patients 
with CIDP, although 25% of CIDP patients in this series had a severe reduction in CMAP 
amplitude (Paramanathan et al., 2015). Furthermore, multipoint incremental MUNE has 
shown that spinal muscular atrophy (SMA) is associated with a reduction in CMAP and 
MUNE and increase in measures of unit size with a lower MUNE correlating with a lower 
function score (Gawel et al., 2015). The lack of correlations between CMAP Scan features 
and clinical features in MMN patients in the current study may relate to the highly individual 
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and variable course of MMN and the effects of IVIg on the natural history of the disorder. 
Furthermore, we only studied a single muscle which may not be reflective of the overall 
disease process given the patchy nature of MMN, although all patients had ipsilateral median 
nerve involvement. The current CMAP Scan method has been most extensively studied in the 
APB muscle. Small muscles are best suited to the CMAP Scan to limit movement artefact 
and ensure patient tolerability. Ulnar-innervated muscles such as abductor digiti minimi and 
first dorsal interosseous are further muscles that could be studied and incorporated into a 
neurophysiological score which may be more sensitive for long-term monitoring.  
 
Limitations of the study include the relatively small number of patients given the rare nature 
of the conditions studied. Further studies of motor unit properties in nerves not affected by 
conduction block may provide information about whether axonal degeneration is a direct 
consequence of conduction block or whether it may be a more generalised process in MMN.  
 
5. CONCLUSIONS 
MMN is associated with marked axonal degeneration to which NCS are insensitive due to the 
process of motor unit remodelling and reinnervation. Once a CMAP reduction has occurred, 
axonal loss is severe and compensatory reinnervation may no longer be adequate to 
compensate. Hence aims of treatment in MMN should be to address axonal loss before a 
significant decline in CMAP amplitude occurs. The CMAP Scan used in the present study 
may be a practical way to monitor disease progression and treatment response in MMN. 
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Table 1. Clinical Features of MMN Patients. 
 Sex Age Age at 
onset 
(years) 
Disease 
duration 
(years) 
E-MRC SS 
(/150) 
GM-1 IgM 
Antibody 
Patient 1 F 70 47 23 117 No 
Patient 2 M 45 39 6 141 No 
Patient 3 F 53 33 17 126 Yes 
Patient 4 M 71 66 5 122 Yes 
Patient 5 M 35 32 3 138 No 
Patient 6 F 66 43 23 139 Yes 
Patient 7 M 41 31 10 143 Yes 
Patient 8 F 56 50 6 142 Yes 
Total 4:4 (M:F) 54.6 ± 13.6 
(35 – 71)* 
42.6 ± 11.8 
(31 – 66)* 
11.6 ± 8.2 
(3 – 23)* 
133 ± 10 
(117 - 143)* 
5/8 
(62.5%) 
 
*=mean ± SD 
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Table 2. Median nerve neurophysiology findings in MMN Patients. 
 Side Distal 
CMAP 
amp 
(mV) 
Elbow 
CMAP 
amp 
(mV) 
CMAP 
area 
reduction 
(%) 
Forearm 
CV (m/s) 
Number 
of Units 
Size of 
largest 
unit (mV) 
Patient 1 Right 6.4 3.8 30 49.7 30 1.1 
Patient 2 Left 7.1 1.8 58 48.4 40 1.1 
Patient 3 Right 7.2 3.9 30 39.6 31 1.2 
Patient 4 Left 10.4 1.9 52 53 41 1.1 
Patient 5 Right 8.8 1.5 78 43.7 45 1.0 
Patient 6 Left 11.2 0.6 93 13.3 38 0.9 
Patient 7 Right 6.3 3.9 40 50 10 2.5 
Patient 8 Right 7.0 2.7 51 58.7 25 0.7 
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Table 3. Summary of results from CMAP scan. 
 MMN 
(n=8) 
HC (n=30) P-value 
(MMN vs HC) 
MScan Peak (mV) 7.6 ± 1.8 8.7 ± 2.5 ns 
MUNE 33 ± 11 93 ± 36 <0.0001 
Largest Unit (mV) 1.2 ± 0.5 0.4 ± 0.1 <0.0005 
Largest Unit (%age of 
MScan Peak) 
16.2 ± 6.3. 5.3 ± 1.9 <0.0001 
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Figure 1. Results of CMAP scan. 
Figure legend: There was no significant difference in MScan Peak between the MMN and 
healthy control group (A); There was a marked reduction in the number of units in the MMN 
group compared with healthy controls (B); MMN patients had a much higher Size of largest 
unit compared with healthy controls (C and D). 
HC: healthy controls 
 
Figure 2. CMAP Scan Example. 
Figure legend: Example of CMAP Scan in a subject with MMN demonstrating large units 
with “gaps” in the CMAP Scan (A). In contrast, the healthy control subject has a similar 
MScan Peak, but with many more units and without large “gaps” in the scan (B).  
 
Figure 3. CMAP Scan Correlations between MScan Peak, MUNE and age. 
Figure legend: Negative correlation between age and MUNE (A) and positive correlation 
between MScan Peak and MUNE (B) in healthy controls (black circles and line). These 
correlations were lost in the MMN group (blue circles and line) 
MUNE: motor unit number estimate 
 
ABSTRACT  
Objective: To estimate the degree of axonal loss in patients diagnosed with multifocal motor 
neuropathy (MMN) using a novel assessment of motor unit numbers and size. Methods: 
Automated motor unit number estimation using a compound muscle action potential (CMAP) 
scan was undertaken in median nerves with conduction block. Results were compared with 
30 age-matched healthy controls. Results: Compared with healthy controls, MMN patients 
had fewer motor units (MMN: 33 ± 11 vs HC: 93 ± 36 [mean ± SD]; p<0.0001) and larger 
‘size of the largest unit’ (MMN: 1.2 ± 0.5mV vs HC: 0.4 ± 0.1mV; p<0.0001), despite having 
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normal distal CMAP amplitudes (MMN: 7.6 ± 1.8mV vs HC: 8.7 ± 2.5mV; p=0.24). 
Conclusions: MMN is associated with marked axonal loss which may be masked by striking 
re-innervation resulting in preservation of distal CMAP amplitudes. Significance: Assessment 
of motor unit properties should be incorporated into assessment of disease progression in 
MMN, given that nerve conduction studies are insensitive to motor unit remodelling. 
 
 
  
  
  
